How a key tooth protein builds and could help rebuild enamel
Amelogenin Nanoribbons In Enamel Development And Engineering
Researchers are learning how the tooth protein amelogenin forms tiny ribbon-shaped structures that guide enamel formation so the knowledge can help rebuild or recreate strong enamel for people with weakened or missing enamel.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11298968 on NIH RePORTER |
What this research studies
This project focuses on amelogenin, the main protein in developing tooth enamel, and how it self-assembles into nanoscale ribbon structures that steer mineral growth. In the lab scientists produce and manipulate these nanoribbons, mimic the action of the enamel enzyme MMP20 that cuts the protein, and add acidic partners to trigger deposition of a calcium phosphate layer that later crystallizes into hard apatite. They use biochemical tests, nanoscale imaging, and model systems that imitate enamel formation to watch each step of this process. The work aims to map the stepwise events that create natural enamel so researchers can design materials or treatments that recreate its strength and structure.
Who could benefit from this research
Good fit: Ideal candidates would be people with hereditary or acquired enamel defects (such as amelogenesis imperfecta, severe enamel erosion, or childhood enamel hypoplasia) or individuals willing to donate extracted teeth or dental tissue for research.
Not a fit: Patients whose problems are unrelated to enamel structure—for example advanced gum disease, jawbone infections, or oral cancers—are unlikely to receive a direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could lead to new ways to rebuild or strengthen tooth enamel, lowering cavities, sensitivity, and the need for repeated dental repairs.
How similar studies have performed: Prior laboratory studies have shown amelogenin can form amyloid-like nanoribbons and promote mineral growth, but turning those findings into therapies or restorative materials for patients remains new and unproven.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Habelitz, Stefan Friedrich — University of California, San Francisco
- Study coordinator: Habelitz, Stefan Friedrich
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.